| アブストラクト | Yellow fever vaccination remains the most effective strategy for preventing infection in endemic and travel-associated settings, yet rare severe adverse events such as viscerotropic and neurotropic disease continue to raise safety concerns. Adverse event reports submitted to the Vaccine Adverse Event Reporting System (VAERS) between 2015 and 2025 were analyzed. Disproportionality algorithms were applied to evaluate reporting patterns, with subgroup analyses by age and sex. The most frequent events were local injection-site reactions and mild systemic symptoms, consistent with clinical trial findings. Severe outcomes, including yellow fever vaccine-associated viscerotropic and neurotropic disease, demonstrated strong disproportionality signals despite their rarity. Additional hypersensitivity-related and less traditional preferred terms were also detected across multiple methods. Female recipients showed higher frequencies of local reactions, while severe events were proportionally more common in older individuals. The analysis reaffirms the established safety profile of yellow fever vaccine while highlighting rare but clinically important severe events and emerging signals. Continued post-marketing surveillance and targeted risk communication remain essential to optimize safe vaccine use. |
|---|
| ジャーナル名 | Human vaccines & immunotherapeutics |
|---|
| Pubmed追加日 | 2025/12/10 |
|---|
| 投稿者 | Liang, Guojun; Liu, Qiong; Song, Yang |
|---|
| 組織名 | Department of Joint Surgery and Sports Medicine, Huadu District People's Hospital;of Guangzhou, Guangzhou, Guangdong, China.;Department of Clinical Nutrition, Huadu District People's Hospital of Guangzhou,;Guangzhou, Guangdong, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41368988/ |
|---|
